An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 1. Validity of the Chimpanzee Model

被引:12
作者
Bailey, Jarrod [1 ]
机构
[1] New England Antivivisect Soc, Boston, MA 02108 USA
来源
ATLA-ALTERNATIVES TO LABORATORY ANIMALS | 2010年 / 38卷 / 05期
关键词
chimpanzee; hepatitis C; hepatitis C virus; hepatocellular carcinoma; Pan troglodytes; T-CELL RESPONSES; NON-B-HEPATITIS; MUTATIONS CONFERRING RESISTANCE; INTRAHEPATIC GENE-EXPRESSION; INFECTIOUS MOLECULAR CLONE; SERINE-PROTEASE INHIBITOR; RNA-POLYMERASE INHIBITOR; SINGLE-SOURCE OUTBREAK; 3' UNTRANSLATED REGION; DNA-BASED IMMUNIZATION;
D O I
10.1177/026119291003800501
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The USA is the only significant user of chimpanzees in biomedical research in the world, since many countries have banned or limited the practice due to substantial ethical, economic and scientific concerns. Advocates of chimpanzee use cite hepatitis C research as a major reason for its necessity and continuation, in spite of supporting evidence that is scant and often anecdotal. This paper examines the scientific and ethical issues surrounding chimpanzee hepatitis C research, and concludes that claims of the necessity of chimpanzees in historical and future hepatitis C research are exaggerated and unjustifiable, respectively. The chimpanzee model has several major scientific, ethical, economic and practical caveats. It has made a relatively negligible contribution to knowledge of, and tangible progress against, the hepatitis C virus compared to non-chimpanzee research, and must be considered scientifically redundant, given the array of alternative methods of inquiry now available. The continuation of chimpanzee use in hepatitis C research adversely affects scientific progress, as well as chimpanzees and humans in need of treatment. Unfounded claims of its necessity should not discourage changes in public policy regarding the use of chimpanzees in US laboratories.
引用
收藏
页码:387 / 418
页数:32
相关论文
共 327 条
[1]   SERUM ALANINE AMINOTRANSFERASE OF DONORS IN RELATION TO THE RISK OF NON-A,NON-B HEPATITIS IN RECIPIENTS - THE TRANSFUSION-TRANSMITTED VIRUSES STUDY [J].
AACH, RD ;
SZMUNESS, W ;
MOSLEY, JW ;
HOLLINGER, FB ;
KAHN, RA ;
STEVENS, CE ;
EDWARDS, VM ;
WERCH, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (17) :989-994
[2]   Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins [J].
Abraham, JD ;
Himoudi, N ;
Kien, F ;
Berland, JL ;
Codran, A ;
Bartosch, B ;
Baumert, T ;
Paranhos-Baccala, G ;
Schuster, C ;
Inchauspé, G ;
Kieny, MP .
VACCINE, 2004, 22 (29-30) :3917-3928
[3]   Extrahepatic disease manifestations of HCV infection: some current issues [J].
Agnello, V ;
De Rosa, FG .
JOURNAL OF HEPATOLOGY, 2004, 40 (02) :341-352
[4]   Non-human primate surrogate model of hepatitis C virus infection [J].
Akari, Hirofumi ;
Iwasaki, Yuki ;
Yoshida, Tomoyuki ;
Iijima, Sayuki .
MICROBIOLOGY AND IMMUNOLOGY, 2009, 53 (01) :53-57
[5]   Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C [J].
Albert, Matthew L. ;
Decalf, Jeremie ;
Pol, Stanislas .
JOURNAL OF HEPATOLOGY, 2008, 49 (06) :1069-1078
[6]   DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS [J].
ALTER, HJ ;
PURCELL, RH ;
SHIH, JW ;
MELPOLDER, JC ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1494-1500
[7]   Hepatitis C virus and eliminating post-transfusion hepatitis [J].
Alter, HJ ;
Houghton, M .
NATURE MEDICINE, 2000, 6 (10) :1082-1086
[8]  
ALTER HJ, 1978, LANCET, V1, P459
[9]   CLINICAL AND SEROLOGICAL ANALYSIS OF TRANSFUSION-ASSOCIATED HEPATITIS [J].
ALTER, HJ ;
HOLLAND, PV ;
MORROW, AG ;
PURCELL, RH ;
FEINSTONE, SM ;
MORITSUGU, Y .
LANCET, 1975, 2 (7940) :838-841
[10]  
Alter HJ., 1989, CURRENTPROSPECTIVES, P83